

<b>Name of the Issuer:</b>	<b>HEALTHCARE GLOBAL ENTERPRISES LIMITED</b>
----------------------------	--

<b>1 Type of Issue (IPO / FPO)</b>	IPO
<b>2 Issue Size (Rs. Cr)</b>	649.64
- Fresh Issue Size (Rs. Cr)	252.88
- Offer for Sale Component (Rs. Cr)	396.76

Source: Prospectus dated March 22, 2016

<b>3 Grade of issue along with name of the rating agency</b>	
<b>Name</b>	Not Applicable
<b>Grade</b>	Not Applicable

<b>4 Subscription Level (Number of times)</b>	1.31*
Source: Basis of Allotment as finalized in consultation with the National Stock Exchange of India Limited ("NSE")	
*The above figure is after technical rejections and represents 18,749 valid applications with a total of 39,044,460 equity shares bid (including Anchor Investor Portion)	

<b>5 QIB Holding (as a % of outstanding capital) as disclosed to stock exchanges</b>	
<b>Particulars</b>	<b>%</b>
(i) allotment in the issue <sup>(1)</sup>	30.25%
(ii) at the end of 1st FY (March 31, 2016) <sup>(2)</sup>	50.08%
(iii) at the end of 2nd FY (March 31, 2017) <sup>(2)</sup>	48.71%
(iv) at the end of 3rd FY (March 31, 2018)*	Not Available
* QIB Holding not disclosed as reporting for the relevant fiscal year has not been completed.	
(1) Source: Basis of Allotment. It excludes pre-issue holding by QIBs and includes allotment to Anchor Investors	
(2) Source: Stock Exchange Website	

<b>6 Financials of the issuer</b>	(In Rs. Crore)		
<b>Parameters</b>	<b>1st FY (March 31, 2016)</b>	<b>2nd FY (March 31, 2017)</b>	<b>3rd FY (March 31, 2018)*</b>
Income from operations	575.9	700.11	Not Available
Net Profit for the period	5.45	23.04	Not Available
Paid-up equity share capital	85.08	85.71	Not Available
Reserves excluding revaluation reserves	451.1	404.37	Not Available
* Financials not available as reporting for the relevant fiscal year has not been completed.			

<b>7 Trading Status in the scrip of the issuer</b>	
Company's Equity Shares shall be listed on both the BSE Limited ("BSE") and the National Stock Exchange of India Limited ("NSE"). The Shares have not been suspended or delisted.	
<b>Particulars</b>	<b>Status</b>
(i) at the end of 1st FY (March 31, 2016)	Frequently traded
(ii) at the end of 2nd FY (March 31, 2017)	Frequently traded
(iii) at the end of 3rd FY (March 31, 2018)*	Not Available
* Trading status not available as the relevant fiscal year has not been completed.	

**8 Change in Directors of issuer from the disclosures in the offer document**

Particulars	Name of the Director	Appointed / Resigned
(i) at the end of 1st FY (March 31, 2016)	Nil	Nil
(ii) at the end of 1st FY (March 31, 2017)	Mr. Prakash Parthasarathy	Retired
	Dr. B. S. Ramesh	Appointment
	Dr. Amit Varma	Appointment
(iii) at the end of 1st FY (March 31, 2018)*	Not Available	Not Available

Source: Stock Exchange Filings

\* Changes in Directors not available as the relevant fiscal year has not been completed.

**9 Status of implementation of project/ commencement of commercial production**

(i) as disclosed in the offer document	Not applicable
(ii) Actual implementation	Not applicable
(iii) Reasons for delay in implementation, if any	Not applicable

**10 Status of utilization of issue proceeds**

(i) as disclosed in the offer document

(Rs. Crore)

Expenditure Items	Amount	Estimated utilization up to March 31, 2017	Estimated utilization up to March 31, 2018	Estimated utilization up to March 31, 2019
Purchase of medical equipment	42.21	42.21	-	-
Investment in IT software, services and hardware	30.19	5.40	16.11	8.68
Pre-payment of debt	147.05	147.05	-	-
General corporate purposes	19.77	10.00	9.77	-
Issue related expenses	13.66	-	-	-
<b>Total</b>	<b>252.88</b>	<b>204.65</b>	<b>25.89</b>	<b>8.68</b>

Source: Prospectus dated March 22, 2016

(ii) Actual utilization

(Rs. Crore)

Expenditure Items	Amount to be financed from Gross Proceeds as disclosed in the offer document*	Amount utilized up to March 31, 2017	Amount utilized up to March 31, 2018	Amount utilized up to March 31, 2019
Purchase of medical equipment	42.21	Nil	-	-
Investment in IT software, services and hardware	30.19	2.55	-	-
Pre-payment of debt	147.05	147.00	-	-
General corporate purposes	19.77	Nil	-	-
Issue related expenses	13.66	NA	-	-
<b>Total</b>	<b>252.88</b>	<b>149.55</b>	<b>-</b>	<b>-</b>

Source: Prospectus dated March 22, 2016, BSE Filing

(iii) Reasons for deviation, if any  
Not Applicable

**11 Comments of monitoring agency, if applicable**

(a) Comments on use of funds	
(b) Comments on deviation, if any, in the use of proceeds of the issue from the objects stated in the offer document	Since the Net Proceeds of the Fresh Issue is less than Rs. 500 crore, the Company is not required to appoint a monitoring agency.
(c) Any other reservations expressed by the monitoring agency about the end use of funds	

12 Pricing Data

Issue Price (Rs.): 218  
 Designated Stock Exchange: NSE  
 Listing Date: 30-Mar-16

Price parameters	At close of listing day (March 30, 2016)	At close of 30th calendar day from listing day (April 28, 2016) <sup>(1)</sup>	At close of 90th calendar day from listing day (July 27, 2016) <sup>(2)</sup>	As at the end of 1st FY after the listing of the issue (March 31, 2016) <sup>(3)</sup>			As at the end of 2nd FY after the listing of the issue (March 31, 2017) <sup>(3)</sup>			As at the end of 3rd FY after the listing of the issue (March 31, 2018) <sup>(3)(4)</sup>		
				Closing price	High (during the FY)	Low (during the FY)	Closing price	High (during the FY)	Low (during the FY)	Closing price	High (during the FY)	Low (during the FY)
Market Price on Designated Stock Exchange	171.00	184.60	196.55	178.55	211.90	167.45	229.45	264.90	167.00	Not Available	Not Available	Not Available
SNP CNX Nifty	7,735.20	7,847.25	8,615.80	7,738.40	8,844.80	6,825.80	9,173.80	9,218.40	7,516.85	Not Available	Not Available	Not Available
BSE SENSEX	25,338.58	25,603.10	28,024.33	25,341.86	29,094.61	22,494.61	29,620.50	29,824.62	24,523.20	Not Available	Not Available	Not Available

Note:

- (1) 30th calendar day shall be taken as listing date plus 29 calendar days.  
 (2) 90th calendar day shall be taken as listing date plus 89 calendar days.  
 (3) High and Low based on intra day prices  
 (4) Pricing data not disclosed as the relevant fiscal year has not completed

13 Basis for Issue Price

Accounting ratio	As disclosed in the offer document <sup>(1)</sup>	At the end of 1st FY (March 31, 2016) <sup>(2)</sup>	At the end of 2nd FY (March 31, 2017) <sup>(2)(3)</sup>	At the end of 3rd FY (March 31, 2018) <sup>(3)(3)</sup>	
<b>Issuer:</b>					
	Consolidated	0.08	0.17	2.69	Not Available
<b>Peer Group:</b>					
EPS	Apollo Hospitals Enterprise Limited	24.43	23.79	20.50	Not Available
	Fortis Healthcare Limited	(3.11)	(0.97)	9.19	Not Available
	Narayana Hrudayalaya Limited	(0.88)	0.95	4.10	Not Available
	<b>Industry Avg:</b>	NA	NA	NA	NA
<b>Issuer:</b>					
	Consolidated	2725.00	1,050.29	85.30	Not Available
<b>Peer Group:</b>					
P/E	Apollo Hospitals Enterprise Limited	60.08	55.67	56.91	Not Available
	Fortis Healthcare Limited	-	-	19.60	Not Available
	Narayana Hrudayalaya Limited	-	300.74	76.46	Not Available
	<b>Industry Avg:</b>	60.08	178.20	50.99	Not Available
<b>Issuer:</b>					
	Consolidated	0.20%	1.02%	4.70%	Not Available
<b>Peer Group:</b>					
RoNW	Apollo Hospitals Enterprise Limited	10.72%	9.15%	7.96%	Not Available
	Fortis Healthcare Limited	-3.55%	-1.73%	7.59%	Not Available
	Narayana Hrudayalaya Limited	-2.18%	4.56%	8.61%	Not Available
	<b>Industry Avg:</b>	1.66%	4.00%	8.06%	Not Available

		<b>Issuer:</b>				
		Consolidated	36.26	63.02	57.17	Not Available
		<b>Peer Group:</b>				
NAV per share	Apollo Hospitals Enterprise Limited	227.87	248.24	257.25	Not Available	
	Fortis Healthcare Limited	87.46	86.31	121.89	Not Available	
	Narayana Hrudayalaya Limited	38.42	43.40	47.12	Not Available	
	Industry Avg:	NA	NA	NA	NA	

**Notes:**

- (1) Sourced from Prospectus dated March 22, 2016. Disclosure is based on the consolidated financial information disclosed in the Prospectus for Fiscal 2015.  
(2) Disclosure is based on the financial results filed with the Stock Exchange  
(3) Information not provided as the relevant fiscal year has not completed  
Key ratios for the Company for the three fiscal years stated above shall be calculated as follows:  
(i) EPS - Fully diluted EPS as reported by the Company in its Annual Report.  
(ii) P/E - Closing Price as of relevant fiscal year end / EPS  
(iii) RoNW - Net Profit After Tax / Closing networth (Share Capital + Reserves and Surplus - Miscellaneous expenses)  
(iv) NAV per share - Closing Networth / Shares Outstanding as of fiscal year end

**14 Any other material information**

<b>Date of disclosure to Designated Stock Exchange</b>	<b>Announcement</b>	
22-Apr-16	HCG launches state-of-the-art Comprehensive Cancer Centre in Vizag	
7-May-16	HCG Launches Advanced Comprehensive Cancer Centre in Baroda	
12-Aug-16	Appointed Mr. Yogesh Patel as the Chief Financial Officer of the Company, arising out of the resignation of Mr. Krishnan Subramanian.	
5-Nov-16	HealthCare Global Enterprises Ltd has entered in to a Shareholders' Agreement on November 03, 2016, with Pinnacle Hospitals India Private Limited, relating to the Company's investment in HCG Pinnacle Oncology Private Limited, a subsidiary of the Company, setting out the relationship between the parties, their rights, obligations as shareholders in HCG Pinnacle Oncology Private Limited; and other matters in connection therewith.	
17-Nov-16	Informed that Company proposed to merge DKR Healthcare Private Limited, a subsidiary of BACC Health Care Private Limited, with BACC Health Care Private Limited, being subsidiaries of the Company	
24-Nov-16	Entered into a Joint Venture Agreement on November 22, 2016, with HCG Regency Oncology Healthcare Pvt. Ltd, a subsidiary of the Company and Regency Hospital Limited setting out the relationship between the parties, their rights, obligations as shareholders in HCG Regency Oncology Healthcare Pvt. Ltd; and other matters in connection therewith.	
17-May-17	Launch of HCG Regency Oncology Centre in Kanpur	
2-Jun-17	Execution of Share Purchase Agreement with Pinnacle Hospitals India Private Limited.	

Source: Stock Exchange Filings